Santaris Pharma A/S Announces Expanded Worldwide Strategic Alliance With Pfizer Inc. Directed to Development of RNA-targeted Medicines

HOERSHOLM, Denmark and SAN DIEGO, Jan. 4, 2011 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc. (NYSE: PFE), today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

The Santaris Pharma A/S LNA Drug Platform is the only RNA technology with both mRNA and microRNA targeted drugs in clinical trials, demonstrating the broad utility of the proprietary platform. The unique combination of small size and high affinity achievable with Santaris Pharma A/S LNA technology allows LNA-based drugs to potently and specifically inhibit RNA targets in different tissues without the need for complex delivery vehicles.

(read the entire release… )